Balaji Prasad
Stock Analyst at Barclays
(2.43)
# 2,428
Out of 4,944 analysts
132
Total ratings
42.74%
Success rate
-0.01%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.40 | +290.63% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $9.02 | +21.95% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $24.81 | -3.26% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $10.12 | -11.07% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $113.33 | +76.48% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $17.43 | +9.01% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $51.36 | +16.82% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $149.77 | +62.92% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.05 | +165.19% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $29.68 | -25.88% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $652.27 | -20.28% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.60 | +56.63% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.91 | +22.21% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.66 | +107.85% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.42 | +192.40% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.92 | +664.28% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.40
Upside: +290.63%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $9.02
Upside: +21.95%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $24.81
Upside: -3.26%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $10.12
Upside: -11.07%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $113.33
Upside: +76.48%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $17.43
Upside: +9.01%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $51.36
Upside: +16.82%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $149.77
Upside: +62.92%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.05
Upside: +165.19%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $29.68
Upside: -25.88%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $652.27
Upside: -20.28%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.60
Upside: +56.63%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.91
Upside: +22.21%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.66
Upside: +107.85%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.42
Upside: +192.40%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.92
Upside: +664.28%